Abstract:Brain metastases (BM), with a dismal prognosis, are a common and lethal complication of non-small cell lung cancer. Approximately, 10% patients present with BM at their initial diagnosis. Although, surgery and/or radiation therapy remain to be the mainstay treatment, targeted therapies are finding increasing application in treating BM. However, due to the very limited accessibility of brain lesions, its genomic and epigenomic landscape remain elusive. Capture-based targeted sequencing for somatic mutation profiling was performed on 27 treatment-naïve advanced NSCLC patients with paired lung primary and BM lesions using a pane consisting of 520 cancer related genes. DNA methylation analyses was performed on same samples using a DNA methylation panel consisting of 100,000 CpG sites. Collectively, we identified 370 (291 SNVs+Indels, 78 CNVs and 1 rearrangement) and 574 (245 SNVs+Indels, 327 CNVs and 2 rearrangements) mutations from lung primary lesions and BM, respectively. Among them, 242 mutations were shared; 128 were lung primary-specific and 332 were BM-specific. Among the BM specific mutations, a majority of them (82%, 272/332) were copy number variations (CNVs). Only 16% of CNVs were shared by lung lesions and BM. The concordance for SNVs and indels were much higher-54% between the two sources of tissues. Furthermore, we observed a much higher concordance rate (79%) in TP53 and classic lung cancer driver genes than other genes (p<0.001), indicating that they might be stem mutations. Next, we performed pathway analysis of genes that were only mutated in BM and revealed an enrichment of genes participating in PI3K-AKT and focal adhesion pathways. We also compared tumor mutation burden (TMB) between them and revealed comparable TMB (p=0.1). Our DNA methylation analysis revealed distinct methylation patterns with 268 blocks that are significantly differentially methylated between primary lung lesions and BM. Among them, 211 blocks were hypermethylated in BM and the remaining 57 blocks were hypermethylated in lung lesions. These blocks were enrichment in genes participating in cell adhesion, Rap1 signaling and calcium signaling pathways. We revealed diverse somatic mutation and DNA methylation profiles between lung primary lesions and BM. BM had significantly more unique CNVs. A great concordance was observed for classic lung cancer driver genes and TP53. Our study provided a comprehensive view of genomic and DNA methylation profiling for lung primary lesions and BM, paving the avenue for the development of targeted therapies for treating BM.

Figure S4 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 as a Key Protein in Promoting Bone Metastases in Lung Cancer

Figure S3 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 as a Key Protein in Promoting Bone Metastases in Lung Cancer

Figure S2 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 As a Key Protein in Promoting Bone Metastases in Lung Cancer

Figure S6 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 as a Key Protein in Promoting Bone Metastases in Lung Cancer

Data from Mass Spectrometry–Based Proteomics Identifies Serpin B9 As a Key Protein in Promoting Bone Metastases in Lung Cancer

Mass spectrometry-based proteomics identifies Serpin B9 as a key protein in promoting bone metastases in lung cancer

Figure S1 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 As a Key Protein in Promoting Bone Metastases in Lung Cancer

Figure S5 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 As a Key Protein in Promoting Bone Metastases in Lung Cancer

Figure S7 from Mass Spectrometry–Based Proteomics Identifies Serpin B9 as a Key Protein in Promoting Bone Metastases in Lung Cancer

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

Bone Morphogenetic Protein 9 Overexpression Reduces Osteosarcoma Cell Migration and Invasion

Bone Morphogenetic Protein 9 Regulates the Cross-Talk Between Breast Cancer Cells and Bone Marrow Mesenchymal Stem Cells

P1.01-18 Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases

Effects of human bone morphogenetic protein 9 on migration and apoptosis of human breast cancer cells in simulated bone microenvironment in vitro

BMP9 Inhibits Proliferation and Metastasis of HER2-positive SK-BR-3 Breast Cancer Cells Through ERK1/2 and PI3K/AKT Pathways.

Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Predictive Significance Of Bone Sialoprotein And Osteopontin For Bone Metastases In Resected Chinese Non-Small-Cell Lung Cancer Patients: A Large Cohort Retrospective Study

Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure S2 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

BMP9 Inhibits the Growth and Migration of Lung Adenocarcinoma A549 Cells in a Bone Marrow Stromal Cell‑derived Microenvironment Through the MAPK/ERK and NF-κB Pathways.